In a 22-year-old man with a history of lithium, quetiapine, and fluoxetine use who develops malignant hyperthermia after succinylcholine administration, presenting with fever, tachycardia, hypotension, diffuse muscular rigidity, rising end‑tidal CO₂, elevated plateau pressures, and severe respiratory acidosis, what is the next best treatment?

Immediate Administration of Dantrolene

The next best treatment is dantrolene, administered immediately at an initial dose of 2-3 mg/kg IV, with repeated doses of 1 mg/kg every 5 minutes until the end-tidal CO₂ normalizes and core temperature falls below 38.5°C. This patient is experiencing a classic malignant hyperthermia (MH) crisis triggered by succinylcholine administration, and dantrolene is the only specific, life-saving pharmacologic treatment for this condition 1, 2.

Clinical Recognition

This presentation is pathognomonic for malignant hyperthermia:

• Trigger exposure: Succinylcholine used for intubation
• Rising end-tidal CO₂: Progressive increase from 45 to 75 mmHg despite aggressive ventilation adjustments
• Hyperthermia: Temperature of 102°F (38.9°C)
• Diffuse muscle rigidity: Classic finding in MH
• Severe respiratory acidosis: pH 7.16, PaCO₂ 73 mmHg
• Hemodynamic instability: Hypotension (72/54 mmHg) and tachycardia (138/min)
• Elevated plateau pressures: 35 cm H₂O, reflecting muscle rigidity

The European Malignant Hyperthermia Group guidelines explicitly state that treatment should start as soon as an MH crisis is suspected, and the clinical presentation here is unequivocal 1.

Why Dantrolene is the Answer

Dantrolene is the only definitive treatment for malignant hyperthermia 1, 2, 3. It works by inhibiting calcium release from the sarcoplasmic reticulum in skeletal muscle, directly reversing the pathophysiologic mechanism of MH. The FDA drug label for succinylcholine explicitly states: "Intravenous dantrolene sodium is recommended as an adjunct to supportive measures in the management of this problem" 3.

Specific Dosing Protocol

Per the most recent guidelines 2, 4:

• Initial dose: 2-3 mg/kg IV (approximately 140-210 mg for a 70 kg patient)
• Repeat dosing: 1 mg/kg every 5 minutes until treatment goals achieved
• Treatment endpoints:
  • End-tidal CO₂ < 6 kPa (45 mmHg) with normal minute ventilation
  • Core temperature < 38.5°C
  • Resolution of muscle rigidity
• Maximum dose: May need to exceed the traditional 10 mg/kg maximum in fulminant cases
• Preparation: Each 20 mg vial requires mixing with 60 mL sterile water; at least 36-50 vials may be needed 1

Why Not the Other Options

Cisatracurium is a non-depolarizing neuromuscular blocker that would only mask the rigidity without treating the underlying hypermetabolic crisis. It does not address the calcium dysregulation driving MH and would be dangerous as it could obscure clinical monitoring of treatment response.

Bromocriptine is used for neuroleptic malignant syndrome (NMS), not MH. While this patient takes quetiapine, the temporal relationship to succinylcholine exposure, the rapidity of onset, and the classic MH presentation make this diagnosis certain. NMS typically develops over days, not minutes to hours after anesthetic exposure 5.

Midazolam and fosphenytoin would be appropriate for status epilepticus but have no role in MH treatment. This patient's obtundation is from the hypermetabolic crisis and sedatives used for intubation, not seizures.

Emergency hemodialysis might eventually be needed for severe hyperkalemia or myoglobinuric renal failure as complications of MH, but it is not the immediate priority. The primary pathology must be reversed first with dantrolene 1.

Concurrent Management Steps

While administering dantrolene, simultaneously implement these measures per EMHG guidelines 1:

1. Hyperventilate aggressively: Increase minute ventilation 2-3 times normal with 100% FiO₂ (already being done)
2. Active cooling:
   • 2000-3000 mL chilled (4°C) 0.9% saline IV
   • Surface cooling with cold sheets, fans, ice packs to axillae and groin
   • Stop cooling once temperature < 38.5°C
3. Treat acidosis: Sodium bicarbonate IV if pH < 7.2 (this patient's pH is 7.16) 1
4. Manage hypotension: Aggressive crystalloid resuscitation; avoid calcium channel blockers with dantrolene
5. Monitor for hyperkalemia: Check potassium urgently; treat with dextrose/insulin and calcium chloride if elevated
6. Ensure adequate urine output: Target > 2 mL/kg/hr with furosemide and mannitol to prevent myoglobin-induced renal failure 1

Critical Pitfalls to Avoid

• Do not delay dantrolene administration while pursuing other interventions. Every minute counts in MH, and mortality increases dramatically with delayed treatment.
• Do not use calcium channel blockers (like verapamil or diltiazem) for arrhythmias in the presence of dantrolene, as this combination can cause severe hyperkalemia and cardiovascular collapse.
• Do not assume adequate dosing after initial response. Dantrolene must be continued until all treatment endpoints are met; recrudescence can occur if treatment is stopped prematurely 4.
• Do not confuse this with serotonin syndrome despite the patient's fluoxetine use. The succinylcholine trigger, rapidity of onset, and muscle rigidity pattern are diagnostic for MH.

Post-Crisis Management

After stabilization, this patient requires 1, 2:

• ICU monitoring for minimum 24 hours
• Serial CK, potassium, myoglobin, renal function, and coagulation studies
• Referral to a malignant hyperthermia investigation unit for diagnostic testing (in vitro contracture testing and genetic testing)
• Patient and family counseling about MH susceptibility
• Medical alert identification
• Avoidance of all triggering agents (volatile anesthetics and succinylcholine) for future procedures